Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:CADL NASDAQ:DRUG NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.98+2.3%$7.06$4.73▼$9.53$721.66M0.4432,517 shs121,796 shsCADLCandel Therapeutics$10.22+6.8%$8.93$4.35▼$11.36$748.67M-0.521.58 million shs557,258 shsDRUGBright Minds Biosciences$77.49+3.9%$72.49$25.77▼$123.75$753.93M-5.34234,484 shs81,481 shsPLXProtalix BioTherapeutics$2.36-2.3%$2.15$1.41▼$3.19$189.75MN/A971,588 shs185,623 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.43%-2.57%+7.57%-8.33%+1.64%CADLCandel Therapeutics-5.99%-0.73%+15.16%+36.71%+41.99%DRUGBright Minds Biosciences-1.98%-1.74%+23.00%-14.65%+185.21%PLXProtalix BioTherapeutics+1.26%+0.84%+8.56%+8.56%+66.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.98+2.3%$7.06$4.73▼$9.53$721.66M0.4432,517 shs121,796 shsCADLCandel Therapeutics$10.22+6.8%$8.93$4.35▼$11.36$748.67M-0.521.58 million shs557,258 shsDRUGBright Minds Biosciences$77.49+3.9%$72.49$25.77▼$123.75$753.93M-5.34234,484 shs81,481 shsPLXProtalix BioTherapeutics$2.36-2.3%$2.15$1.41▼$3.19$189.75MN/A971,588 shs185,623 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.43%-2.57%+7.57%-8.33%+1.64%CADLCandel Therapeutics-5.99%-0.73%+15.16%+36.71%+41.99%DRUGBright Minds Biosciences-1.98%-1.74%+23.00%-14.65%+185.21%PLXProtalix BioTherapeutics+1.26%+0.84%+8.56%+8.56%+66.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50193.70% UpsideCADLCandel Therapeutics 2.60Moderate Buy$18.5781.65% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$143.8385.63% UpsidePLXProtalix BioTherapeutics 3.00Buy$12.00409.55% UpsideCurrent Analyst Ratings BreakdownLatest PLX, AURA, CADL, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026CADLCandel Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.006/29/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/15/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.004/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ACADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/APLXProtalix BioTherapeutics$76.38M2.48$0.13 per share17.80$0.47 per share5.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.98N/AN/AN/AN/A-60.42%-41.33%8/13/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.18N/A7.60N/A-21.03%-30.89%-11.74%N/ALatest PLX, AURA, CADL, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CADLCandel Therapeutics-$0.22N/AN/AN/AN/AN/A8/13/2026Q3 2026DRUGBright Minds Biosciences-$1.2831N/AN/AN/AN/AN/A8/12/2026Q2 2026AURAAura Biosciences-$0.41N/AN/AN/AN/AN/A5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/14/2026Q1 2026CADLCandel Therapeutics-$0.2958-$0.14+$0.1558-$0.14N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09CADLCandel Therapeutics0.3428.0528.05DRUGBright Minds BiosciencesN/A81.4781.47PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%CADLCandel Therapeutics13.93%DRUGBright Minds Biosciences40.52%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences1.90%CADLCandel Therapeutics14.30%DRUGBright Minds Biosciences42.66%PLXProtalix BioTherapeutics6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million101.42 millionNot OptionableCADLCandel Therapeutics6073.27 million62.79 millionOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionablePLXProtalix BioTherapeutics20080.57 million69.00 millionOptionablePLX, AURA, CADL, and DRUG HeadlinesRecent News About These CompaniesProtalix BioTherapeutics, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comPLX: Chiesi Milestone ReceivedMay 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference CallMay 14, 2026 | uk.finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...May 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsMay 13, 2026 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026May 6, 2026 | prnewswire.comProtalix: Elfabrio Struggles Against Oral CompetitionApril 15, 2026 | seekingalpha.comProtalix Revenue Miss Overshadowed By Milestone-Backed 2026 GuidanceMarch 24, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finanznachrichten.deProtalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115March 18, 2026 | seekingalpha.comProtalix BioTherapeutics advances Fabry disease and gout programs during 2025March 18, 2026 | proactiveinvestors.comProtalix: Q4 Earnings SnapshotMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimenMarch 9, 2026 | proactiveinvestors.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase ...March 9, 2026 | tmcnet.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)March 9, 2026 | globenewswire.comProtalix BioTherapeutics (PLX) price target decreased by 12.00% to 11.22February 4, 2026 | msn.comA March Decision That Could Change Protalix BioTherapeutics OutlookFebruary 1, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?By Nathan Reiff | June 29, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026Domino's Stock Slides to 52-Week Low as Investors Digest CEO ChangeBy Jennifer Ryan Woods | June 25, 2026Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?By Dan Schmidt | June 22, 2026New Stock Price Highs Are on the Menu for Darden RestaurantsBy Thomas Hughes | June 29, 2026PLX, AURA, CADL, and DRUG Company DescriptionsAura Biosciences NASDAQ:AURA$6.98 +0.16 (+2.35%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Candel Therapeutics NASDAQ:CADL$10.22 +0.65 (+6.83%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Bright Minds Biosciences NASDAQ:DRUG$77.48 +2.88 (+3.85%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Protalix BioTherapeutics NYSE:PLX$2.36 -0.06 (-2.28%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
